中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

640 records (took 0.031 seconds)

    DEVICES, SYSTEMS, AND METHODS FOR DIAGNOSING TREATING AND MONITORING CHRONIC PELVIC PAIN
    152.
    发明申请
    DEVICES, SYSTEMS, AND METHODS FOR DIAGNOSING TREATING AND MONITORING CHRONIC PELVIC PAIN 有权

    公开(公告)号：US20230053296A1

    公开(公告)日：2023-02-16

    申请号：US17973738

    申请日：2022-10-26

    Applicant: University of Houston System

    Inventor： Yingchun Zhang ,  Nicholas Dias ,  Yang Liu ,  Henry Lai ,  Theresa M. Spitznagle ,  Christopher P. Smith

    IPC: A61B5/397 ,  A61B5/313 ,  G16H20/40

    Abstract: A system for determining a treatment regimen for chronic pelvic pain (CPP) includes an electromyography (EMG) probe including electrodes. Each electrode detects pelvic floor muscle activity. An EMG sensor array includes bipolar EMG sensors configured to detect muscle activity of muscles associated with or supporting the pelvic floor muscles. An EMG amplifier is in communication with the EMG probe or the EMG sensor array. The EMG amplifier includes a plurality of input channels. Each input channel receives data of muscle activity in the pelvic floor muscles or the muscles associated with or supporting the pelvic floor muscles from the EMG probe or the EMG sensor array. A processor of a computer performs muscle network analysis using the data of muscle activity in the pelvic floor muscles or the muscles associated with or supporting the pelvic floor muscles. A treatment regimen for CPP is recommended based on the muscle network analysis.

    DEVICES, SYSTEMS AND METHODS OF MAPPING NEUROMUSCULAR JUNCTIONS FOR BOTULINUM TOXIN INJECTIONS
    154.
    发明申请
    DEVICES, SYSTEMS AND METHODS OF MAPPING NEUROMUSCULAR JUNCTIONS FOR BOTULINUM TOXIN INJECTIONS 有权

    公开(公告)号：US20220395685A1

    公开(公告)日：2022-12-15

    申请号：US17838758

    申请日：2022-06-13

    Applicant: University of Houston System

    Inventor： Yingchun Zhang

    IPC: A61N1/36 ,  A61N1/04 ,  A61B5/389

    Abstract: A system for mapping neuromuscular junctions for botulinum neurotoxin (BoNT) injections includes a stimulation electrode and an electromyography (EMG) sensor array including EMG sensors configured to be arranged about a person's face. Each EMG sensor detects muscle activity of a facial muscle of a facial muscle group. An EMG amplifier includes a plurality of input channels. Each input channel receives data of facial muscle activity in the facial muscle group from the EMG sensor array. A computer is in communication with the EMG amplifier. A processor of the computer identifies neuromuscular junctions (NMJs) of the facial muscle group based on the data of facial muscle activity received from the EMG sensor array. The plurality of NMJs are mapped with respect to the at least one facial muscle group of the body of the person. At least one NMJ site for BoNT injection is recommended by the computer.

    SYSTEM AND METHOD TO MEASURE TISSUE BIOMECHANICAL PROPERTIES WITHOUT EXTERNAL EXCITATION
    155.
    发明申请
    SYSTEM AND METHOD TO MEASURE TISSUE BIOMECHANICAL PROPERTIES WITHOUT EXTERNAL EXCITATION 有权

    公开(公告)号：US20220386862A1

    公开(公告)日：2022-12-08

    申请号：US17882682

    申请日：2022-08-08

    Applicant: University of Houston System

    Inventor： Kirill V. Larin ,  Achuth Nair ,  Manmohan Singh ,  Salavat Aglyamov

    IPC: A61B3/00 ,  A61B3/10 ,  A61B3/16 ,  A61B5/00 ,  A61B8/10 ,  A61B8/08

    Abstract: A system and method for measuring biomechanical properties of tissues without external excitation are capable of measuring and quantifying these parameters of tissues in situ and in vivo. The system and method preferably utilize a phase-sensitive optical coherence tomography (OCT) system for measuring the displacement caused by the intrinsic heartbeat. The method allows noninvasive and nondestructive quantification of tissue mechanical properties. Preferably, the method is used to detect tissue stiffness and to evaluate its stiffness due to intrinsic pulsatile motion from the heartbeat. This noninvasive method can evaluate the biomechanical properties of the tissues in vivo for detecting the onset and progression of degenerative or other diseases and evaluating the efficacy of therapies.

    Superconductor with improved flux pinning at low temperatures
    158.
    发明授权
    Superconductor with improved flux pinning at low temperatures 有权

    公开(公告)号：US11488746B2

    公开(公告)日：2022-11-01

    申请号：US17074223

    申请日：2020-10-19

    Applicant: The University of Houston System

    Inventor： Venkat Selvamanickam

    IPC: H01B12/02 ,  H01L39/24 ,  H01L39/14 ,  H01B1/02 ,  H01B1/08

    Abstract: A REBCO superconductor tape that can achieve a lift factor greater than or equal to approximately 3.0 or 4.0 in an approximately 3 T magnetic field applied perpendicular to a REBCO tape at approximately 30 K. In an embodiment, the REBCO superconductor tape can include a critical current density less than or equal to approximately 4.2 MA/cm2 at 77 K in the absence of an external magnetic field. In another embodiment, the REBCO superconductor tape can include a critical current density greater than or equal to approximately 12 MA/cm2 at approximately 30 K in a magnetic field of approximately 3 T having an orientation parallel to a c-axis.

    MULTIKINASE DEGRADERS
    160.
    发明申请
    MULTIKINASE DEGRADERS 有权

    公开(公告)号：US20220276226A1

    公开(公告)日：2022-09-01

    申请号：US17631003

    申请日：2020-07-28

    Applicant: University of Houston System

    Inventor： Alexander STATSYUK ,  Sandipan Roy CHOWDHURY

    IPC: G01N33/50 ,  A61K47/55 ,  A61K47/54 ,  C07D417/14 ,  C07D401/14

    Abstract: Multikinase degraders described herein contain on one end a Von Hippel-Lindau (VHL) E3 ligase ligand or cereblon E3 ligase recruiter moiety, which bind to the VHL or cereblon E3 ubiquitin ligase (defined as a ubiquitin ligand binding moiety or ULM group), respectively, and on the other end a promiscuous kinase ligand that binds a target protein kinase (defined as a protein/polypeptide targeting moiety or PTM group), such that the target protein is in close proximity to the ubiquitin ligase. This leads to the ubiquitination and subsequent degradation (and inhibition) of the target protein. Specific present multikinase degraders as shown bind about 360 out of 400 tested kinases, showing that they are much more general kinase binders and degraders than any previously reported.

Patent Agency Ranking